Immutep (ASX:IMM) share price jumps 5% on Chinese patent grant

Immutep shares make their walk northwards after a patent was granted on Friday.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price has stepped into the green from the opening of trade on Friday.

Immutep shares are on the move as the company announced it had been granted a Chinese patent on one of its antibody molecules.

Let's investigate further.

A bit of background to set the scene

Immutep advised that Chinese health authorities had granted the company a new patent on Friday. The company was awarded the approval to develop its "LAG-3 immunotherapeutic products".

In humans, the "lymphocyte activation gene-3", also known as LAG-3, acts like an "immune checkpoint" in the internal highways of our body. That means it is important to regulate our immune system so that it only destroys the foreign and nasty cells inside of us. And not our own.

Immutep has developed a "therapeutic antagonist antibody" called IMP701 to target this LAG-3 molecule. It claims that IMP701 "removes the brakes" that prevent our immune system from "responding to and killing cancer cells".

To achieve this result in humans, Immutep has teamed up with global healthcare giant Novartis AG to further develop the IMP701 antibody.

Together, the pair have created a compound called LAG525, a "humanised form" of IMP701 which is currently being investigated in three separate clinical trials.

What did Immutep announce?

From today's announcement, the patent is particularly "directed to" LAG525. This covers how the antibody is made, and its application in treating illnesses.

In fact, the patent was granted under the specific heading of "Antibody molecules to LAG-3 and uses thereof" from the Chinese Patent Office, to demonstrate this point.

As such, the approval follows the "corresponding" Australian, US, European and Japanese patents that have been previously granted on this molecule from 2018 to 2020.

Obtaining patent approval effectively protects the company's compound, and prevents others from making similar copies. Therefore, it stands to reason that Immutep has gained some competitive advantage with the grant of this patent.

Investors seem to think so too, driving the Immutep share price around 5% higher from the market open on Friday.

Immutep shares are now exchanging hands at 52 cents apiece, down from their intraday high of 54 cents each.

Immutep share price snapshot

The Immutep share price has posted a year to date gain of 27%. This extends the previous 12 month's gain of 171%.

Immutep shares have also climbed around 9% in the green over the last month. Moreover, in the last week, the Immutep share price is up 16%.

These results have outpaced the S&P/ASX 200 index (ASX: XJO)'s return of about 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Young girl drinking milk showing off muscles.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the trading week for ASX investors today.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Share Gainers

3 ASX 200 stocks smashing the benchmark this week

These three ASX 200 stocks are leading the charge this week. Here’s how.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Share Gainers

Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

These shares are having a good session on Thursday. But why?

Read more »

A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
Share Gainers

Why Boss Energy, Emeco, Mineral Resources, and Plenti shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Share Gainers

3 ASX 300 shares going gangbusters on Wednesday

Investors are bidding up these three ASX 300 shares today. But why?

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a huge Tuesday for ASX shares, with the index resetting its record high.

Read more »